胃腺癌和淋巴结转移癌中Claudin18.2表达研究

Expression of Claudin18.2 in primary tumor and lymph node metastasis of gastric cancer

目的:探讨Claudin18.2在胃腺癌和淋巴结转移癌中的表达水平及与临床特征之间的关系。方法:收集2010~2022年深圳市龙岗区第三人民医院和济宁医学院附属金乡医院病理科医院胃腺癌患者组织标本和淋巴结转移样本共计110组,运用免疫组织化学方法检测Claudin18.2的水平,按照FAST研究的标准进行Claudin18.2的评分,探讨Claudin18.2在胃腺癌和淋巴结转移癌中的表达差异。同时进一步分析Claudin18.2的表达水平与临床病理学特征之间的关系。结果:患者年龄35~75岁(中位年龄65岁),男和女患者分别为65例和45例。胃腺癌中Claudin18.2的中到强的阳性率为50%(55/110),淋巴结转移癌中观察到中到强Claudin18.2表达阳性率为44.5%(49/110),阳性表达率差异无统计学意义(P>0.05)。不同年龄、性别、部位及临床分期的患者Claudin18.2的表达差异无统计学意义(P>0.05);但Lauren分型中肠型较弥漫型的Claudin18.2的表达明显增高,差异有统计学意义(P<0.05)。结论:胃腺癌患者中Claudin18.2具有较高的阳性率,原发灶和转移灶之间未见明显不同,为使用Claudin18.2抗体靶向治疗筛选患者提供了理论依据。

Objective To investigate the expression of Claudin18.2 in primary tumor and lymph node metastasis of gastric cancer and its relationship with clinical features.Method A total of 110 pairs of tumor tissue samples and lymph node metastasis samples of gastric adenocarcinoma in The Third People's Hospital of Longgang District of Shenzhen and Jinxiang Hospital of Jining Medical College from 2010 to 2022 were collected.The level of Claudin18.2 was detected by immunohistochemical method,and the Claudin18.2 score was performed according to the criteria of FAST study to explore the expression difference of Claudin18.2 in primary gastric cancer and metastatic cancer.At the same time,the relationship between the expression level of Claudin18.2 and clinicopathological features was further analyzed.Results The patients ranged in age from 35 to 75 years(median age 65 years).There are 65 males and 45 females.The positive rate of claudin18.2 was 50%(55/110)in primary tumors and 44.5%(49/110)in lymph node metastases.There was no significant difference between different age,gender,location,and stage for the expression rate of Claudin18.2(P>0.05).But the ex-pression rate of Claudin18.2 in Intestinal type of Lauren classification was significantly higher than that in diffuse type(P<0.05).Conclusion The positive rate of Claudin18.2 in gastric cancer patients is high and no difference was observed between primary and me-tastatic lesion,which provides a theoretical basis for screening patients with Claudin18.2 antibody targeted therapy.